Fresh analysis indicates that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise regimens.
Published data in a leading health publication demonstrates that while obese people can lose about a fifth of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"People buying these drugs should be cognizant of the danger of rapid weight regain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to starting weight in about 18 months.
Weighing Approaches
The study, which looked at 37 of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.
The team point out that people who lose weight through diet and exercise typically experience a slower creep back—around 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Nutrition scientists believe the mode of action of the injections explains the heightened regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone concentrations several times higher than the body's typical production might result in the body to produce less of its endogenous GLP-1, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication results in appetite is no longer kept in check, making overeating a significant risk."
A Lifelong Disease?
Health authorities suggest the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, due to the likelihood of weight regain, the treatment is often ongoing.
This opinion is echoed by drug manufacturers, who note that the findings "underscore the chronic nature of excess weight," similar to managing conditions like diabetes.
Patient Testimonies
People who have discontinued the medication report a intense return of hunger.
"It was like a trigger activating and I was suddenly ravenous," said an individual.
This difficulty is exacerbated if users have not developed lasting dietary or behavioural modifications during therapy.
Growing Use
Survey data suggest that millions of people in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Use is greater among females than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Ultimately, experts emphasize that while the jabs are potent tools for weight loss, they are not a permanent cure and lasting health benefits likely depends on integrated lifestyle management.
